WALTHAM, Mass., Feb. 10, 2026 (GLOBE NEWSWIRE) — Repligen Company (NASDAQ:RGEN) right now introduced that the Firm will report its fourth quarter 2025 monetary outcomes on Tuesday, February 24, 2026. The Firm will difficulty a press launch earlier than the market opens and can host a convention name at 8:30 a.m. ET to debate enterprise updates and monetary outcomes for the three- and twelve- month reporting durations ended December 31, 2025.
The convention name can be accessible by dialing toll-free (800) 715-9871 for home callers and (646) 307-1963 for worldwide callers. No passcode is required for the dwell name. As well as, a webcast can be accessible by way of the Investor Relations part of the Firm’s web site. Each the convention name and webcast can be archived for a time frame following the dwell occasion. You’ll be able to entry the replay on the Investor Relations part of Firm’s web site.
About Repligen Company
Repligen Company is a worldwide life sciences firm that develops and commercializes extremely modern bioprocessing applied sciences and programs that allow efficiencies within the course of of producing organic medication. We’re “inspiring advances in bioprocessing” for the shoppers we serve; primarily biopharmaceutical drug builders and contract improvement and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Administration, Chromatography, Course of Analytics and Proteins. Our company headquarters are positioned in Waltham, Massachusetts, and the vast majority of our manufacturing websites are within the U.S., with extra key websites in Estonia, France, Germany, Eire, the Netherlands and Sweden. For extra details about the our firm see our web site at www.repligen.com, and comply with us on LinkedIn.
This press launch could include forward-looking statements inside the that means of the federal securities legal guidelines. Buyers are cautioned that statements on this press launch which aren’t strictly historic statements together with, with out limitation, statements recognized by phrases like “imagine,” “anticipate,” “could,” “will,” “ought to,” “search,” or “might” and comparable expressions, represent forward-looking statements. Such forward-looking statements are topic to numerous dangers and uncertainties that might trigger precise outcomes to vary materially from these anticipated, together with dangers mentioned sometimes in our filings with the Securities and Change Fee. We expressly disclaim any duty to replace any forward-looking statements, besides as required by regulation.
Repligen Contact:
Jacob Johnson
VP, Investor Relations
(781) 419-0204
buyers@repligen.com
Source link
#Repligen #Report #Fourth #Quarter #Full #Yr #Monetary #Outcomes
